Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.

ABSTRACT: There are currently many patients with multidrug-resistant and extensively drug-resistant tuberculosis. Ongoing transmission of the highly drug-resistant strains and high mortality despite treatment remain problematic. The current strategy of drug discovery and development takes up to a decade to bring a new drug to clinical use. We embarked on a strategy to screen all antibiotics in current use and examined them for use in tuberculosis. We found that ceftazidime-avibactam, which is already used in the clinic for multidrug-resistant Gram-negative bacillary infections, markedly killed rapidly growing, intracellular, and semidormant Mycobacterium tuberculosis in the hollow fiber system model. Moreover, multidrug-resistant and extensively drug-resistant clinical isolates demonstrated g

SUBMITTER: Deshpande D 

PROVIDER: S-EPMC5576880 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature